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Objectives: The introduction of new rotavirus vaccines into the public sphere
makes it necessary to maintain constant surveillance and to heighten public
awareness of the appearance of new rotavirus strains. We describe the molecular
epidemiology of circulating rotavirus strains after vaccine introduction.
Methods: We collected a total of 1070 stool samples from children with gastro-
enteritis from January 2013 to June 2013. The antigenic prevalence of rotavirus
group A was distinguished using enzyme immunoassay. The G and P genotypes of
enzyme immunoassay-positive samples were determined with reverse
transcription-polymerase chain reaction and nucleotide sequencing analysis.
Results: Of the 1070 samples collected, 277 (25.9%) tested positive for rotavi-
ruses by enzyme-linked immunoabsorbent assay. The most prevalent circulating
genotype G was G1 (51.3%), followed by G2 (34.7%) and G9 (10.8%). The pre-
dominant type of genotype P was P[8] (66.1%), followed by P[4] (31.4%). In this
study, nine genotypes were found. G1P[8] was the most prevalent (51.8%), fol-
lowed by G2P[4] (30.5%), G9P[8] (9.9%), and G2P[8] (4.0%). Several unusual
combinations (G1P[4], G3P[9], G3P[8], G4P[6], and G9P[4]) were also identified.
Conclusion: Molecular epidemiological knowledge of rotaviruses is critical for
the development of effective preventive measures, including vaccines. These
data will help us monitor the effectiveness of current rotavirus vaccines.1. Introduction
Rotaviruses (RVs) are the leading cause of acute and
severe gastroenteritis, diarrhea, and malnutrition pri-
marily in children younger than 5 years [1], and areted under the terms of the
) which permits unrestrict
operly cited.
ase Control and Preventionresponsible for approximately 600,000 deaths world-
wide each year [2,3].
RVs belong to the family Reoviridae. The viral
genome consists of 11 segments of double-stranded (ds)
RNA genome that encodes six structural proteinsCreative Commons Attribution Non-Commercial License (http://
ed non-commercial use, distribution, and reproduction in any
. Published by Elsevier Korea LLC. All rights reserved.
Diversity of circulating rotavirus strains 365(VP1e4, VP6, and VP7) and six nonstructural proteins
(NSP1e6) [1]. So far, RVs are subdivided into eight
groups (AeH) on the basis of the antigenic properties or
the amino acid sequences of the inner capsid protein
VP6 [4].
Based on the differences of VP7 and VP4 gene se-
quences, RVs are divided into genotypes G and P,
respectively. To date, at least 27 G and 35 P genotypes
have been reported from humans and a variety of
mammalian and avian species [5]. Of these, 11 G ge-
notypes and 12 P genotypes have been isolated from
humans [6e8]. However, the most commonly isolated
human RV genotypes are a small number of combined
G/P genotypes, such as G1P[8], G2P[4], G3P[8], G4P
[8], and G9P[8] [8,9]. Certain G and P types have been
found to be highly prevalent in different areas around
the world such as G5 types in Brazil and G10 types in
India [10,11]. More recently, a surveillance program
directed by the World Health Organization noted that in
2010 the predominant uncommon strains were G12P[8]
and G12P[6] viruses in Southeast Asia; G2P[6], G3P[6],
and G1P[6] viruses in sub-Saharan Africa; G1P[4] and
G2P[8] viruses in the Western Pacific; and G9P[4] vi-
ruses in the Americas [9].
In South Korea, molecular epidemiological studies
have shown that G2, G4, and G9 were the most isolated
genotypes from 1998 to 2004. G1 was the most pre-
dominant genotype from years 1987 to 1999, and ge-
notypes G2, G3, and G4 were also isolated during the
same period [12]. G11, a rare strain, was also reported
for the first time in South Korea in 2007 [13]. Recently,
there have been changes in the frequency of genotype
isolations from more common G/P combinations with
the exceptions of G1P[8] and G3P[8] to the rare com-
binations of genotypes such as G4P[6] and G2P[8] [14].
These distinct changes in the prevalence of circulating
RV strains suggest that surveillance studies are impor-
tant for the successful vaccine development and efficacy
testing.
Even with the ongoing vaccinations against RVs, RV
infection with high morbidity and mortality occurs. This
indicates that we should take into account the role of RV
vaccines in the natural temporal variability in genotypes
G and P. Two live attenuated RV vaccines were licensed
and became commercially available in South Korea.
RotaTeq (Merck & Company, Inc, Whitehouse Station,
NJ, USA), launched in September 2007, is a vaccine that
consists of five distinct bovine reassortants, and each of
the five vaccine strains contains outer capsid proteins
from a serotype of the human RVs (G1, G2, G3, G4, and
P[8]). Rotarix (GlaxoSmithK-line, Rixensart, Belgium),
licensed in June 2008, consists of a single attenuated
G1P[8] strain of human RV.
The effect of RV vaccines on the natural pattern of
circulating RV strains in human populations is unknown
and difficult to predict. Continuing surveillance is
needed to identify the spectrum of protectionengendered by each vaccine and the effect that each
vaccine may have on circulating strains. Documentation
of long-term temporal changes in RV strain distributions
requires a detailed analysis of targeted monotypes in
circulation prior to and after vaccine introduction.
In this study, we report the distribution of RV ge-
notypes G and P that have been circulated during the
first half of 2013 in Gwangju, South Korea.2. Materials and methods
2.1. Sample collection
From January 2013 to June 2013, a total of 1070 stool
samples were collected from children who were hospi-
talized with acute gastroenteritis symptoms in eight
hospitals, Gwangju, South Korea. Samples were kept at
4C until they were transported to the laboratory for
analysis. Clinical information on age and sex of patients,
dates of disease onset and sample collection, symptoms,
RV vaccination history, etc., was recorded as back-
ground data.
2.2. RV antigen detection
RV antigens were detected in stool supernatants
using enzyme-linked immunoabsorbent assay (ELISA)
with VP6 group-specific antibody (BioTracer Rotavirus
ELISA kit; Biofocus, Uiwang, Korea) according to the
manufacturer’s instructions. Specimens with Optic
Density (OD) absorbance values >0.4 at a 450-nm
wavelength were considered to be positive.
2.3. Reverse transcription-polymerase chain
reaction for genotyping
G and P genotyping was performed using reverse
transcription-polymerase chain reaction (RT-PCR) on
277 RV ELISA positive samples. Fecal specimens were
diluted 1:10 in phosphate-buffered saline. After a thor-
ough mixing, each fecal suspension was centrifuged for
20 minutes at 1000  g, 4C.
RV ds RNA was extracted from 140 mL of 10% fecal
suspensions using an RNA extraction Kit [QIAamp
Viral RNA mini Kit (spin protocol); Qiagen, Inc., Hil-
den, Germany] in accordance with the manufacturer’s
instructions. The extracted RNA was denaturated at
95C for 5 minutes. RT-PCR was performed for RV G
and P genotypes using Accupower Hotstart RT/PCR
premix kit (Bioneer, Daejeon, Korea). We amplified an
881-bp fragment of the VP7 gene with the consensus
forward primer VP7-F (50-ATG TAT GGT ATT GAA
TAT ACC AC-30) and reverse primer VP7-R (50-AAC
TTG CCA CCA TTT TTT CC-30) [15]. We also
amplified an 876-bp fragment of the VP4 gene with the
consensus forward primer Con3 (50-TGG CTT CGC
CAT TTT ATA GAC A-30) and the reverse primer Con2
(50-ATT TCG GAC CAT TTA TAA CC-30) [16]. The
PCR reaction for the VP7 and VP4 gene amplification
Figure 1. Frequencies (%) of G and P genotypes determined
by analysis of strains collected in 2013.
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minutes, followed by PCR activation at 94C for 15
minutes, then 35 cycles of amplification (1 minute at
94C, 1 minute at 50C, and 1 minute at 72C), and a
final extension of 10 minutes at 72C in GeneAmp PCR
system 9700 (Applied Biosystems, Boston, MA, USA).
The PCR products were then electrophoresed on 1.5%
agarose gel.
2.4. Nucleotide sequencing and sequence
analysis
PCR products were purified using QIAquick Gel
Extraction kit (Qiagen GmbH, Hilden, Germany) in
accordance with the manufacturer’s instructions. The
cycle sequencing reaction was carried out with the ABI
PRISM BigDye terminator cycle sequencing reaction kit
(Applied Biosystems, Foster City, CA, USA), and
sequence data were collected by means of an automated
DNA analyzer Applied Biosystems (ABI) Prism 3100
Genetic Analyzer (Life Technologies, Foster City, Cal-
ifornia, USA). Phylogenetic analysis was performed
using the Clustal W algorithm in MEGA 5.0 software
package [17], using the Maximum Likelihood method
for phylogenetic analysis, with 1000 bootstrap
replicates.3. Results
3.1. Frequency of RV infection by vaccination
status
Overall, 774 of 1070 patient records clearly stated the
status of the vaccination, and the previously vaccinated
patients were vaccinated either with RotaTeq or with
Rotarix. Sixty-seven (17.4%) of the 385 vaccinated pa-
tients were infected with RVs, compared to the infection
of 144 (37%) of 389 patients who did not receive the
vaccine (Table 1). Statistical significance in two tests
was assessed. A p value of <0.05 was considered
indicative of a statistically significant difference. All
analyses were performed using IBM SPSS statistics 20
(IBM Korea, Seoul, Korea).
3.2. Frequencies of G and P genotypes
RVs were detected in 277 of 1070 (25.9%) collected
samples. Two hundred of 277 (86.6%) patients with
RV gastroenteritis were older than 5 years. The G
genotype was identified for 274 samples (98.8%), and
the P genotype was identified for 272 (98.2%) RVTable 1. Frequency of rotavirus infection by vaccination status
Rotavirus Vaccinated, n (%)
Positive 67 (17.4)
Negative 318 (82.6)
Total 385 (100)samples. The most prevalently circulating G genotype
was G1 (51.3%, n Z 142), followed by G2 (34.7%,
n Z 96), G9 (10.8%, n Z 30), G3 (1.8%, n Z 8), and
G4 (0.4%, n Z 1). The predominant type of P geno-
type was P[8] (66.1%, n Z 183), which was followed
by P[4] (31.4%, nZ 87), P[6], and P[9] (0.4%, nZ 1)
(Figure 1, Table 2).
3.3. Distribution of G and P genotype
combinations
In total, 272 G and P combinations made up with nine
different genotypes were identified. G1P[8], the most
frequently detected strain, was responsible for 51.8%
(n Z 141) of infections. G2P[4], G9P[8], and G2P[8]
were detected with a prevalence rate of 30.5% (nZ 83),
9.9% (n Z 27), and 4.0% (n Z 11), respectively. In
addition, unusual RV strains were identified, which bore
the genotypes of G1P[4], G3P[9], G3P[8], G4P[6], and
G9P[4] (Table 3). Among the 67 patients who were
vaccinated with RV, the predominant strain was G2P[4]
(40.3%), followed by G1P[8] (39.0%) and G9P[8]
(12.5%). And among the 389 who were not vaccinated,
144 rotavirus positive samples were analyzed, and the.




Table 2. Distribution of rotavirus G and P genotypes in patients with acute gastroenteritic symptoms in Gwangju, South Korea
in 2013.
Genotypes
No. of positive samples
G1 G2 G3 G4 G9 NT Total (%)
P[4] 1 83 3 87 (31.4)
P[6] 1 1 (0.4)
P[8] 141 11 4 27 183 (66.1)
P[9] 1 1 (0.4)
NT 2 3 5 (1.8)
Total (%) 142 (51.3) 96 (34.7) 5 (1.8) 1 (0.4) 30 (10.8) 3 (1.1) 277 (100)
NT Z nontypable.
Diversity of circulating rotavirus strains 367frequencies were as follows: G1P[8] (56.3%), G2P[4]
(28.2%), and G9P[8] (9.86%), which were identified
with the indicated prevalence (Figure 2).4. Discussion
RVs are composed of genetically diverse populations
of segmented ds RNA viruses, which cause gastroen-
teritis in many animal species including humans. From
year to year and from place to place, the prevalence of
human RV G and P types associated with the disease
fluctuates [18].
In the present study, the distribution of the genotype
of Group A RVs in the cases of acute gastroenteritis in
Gwangju, South Korea, was investigated to determine
the efficacy of currently used RV vaccines in South
Korea.
In our study, 1070 fecal specimens were collected
from children hospitalized with diarrhea, and 277
(25.9%) were positive for RV. A nationwide surveil-
lance of RV infection conducted by 16 laboratories of
local public health institutes revealed the infection rate
of RVs in South Korea from 2008 to 2013. The detec-
tion rate of RVs was 8.1% (9048 of 112,344) in Korea
from 2008 to 2011, 5.6% (1057 of 18,731) in 2012, and
7.6% (1430 of 18,908) in 2013 [19]. The RV detection
rate in Gwangju was higher than the average of the
national RV infection rate; it was recorded as 15.1%
(1822 of 12,099) in the Gwangju area from 2008 to
2011, 7.2% (160 of 2212) in 2012, and 25.9% (277 of
1070) in 2013. Although RV vaccination was active, the
number of patients with rotaviral gastroenteritis in 2013Table 3. Genotypic distribution of Group A rotavirus in Gwan





G3P[8] 4 1.5increased by more than three times when compared with
the previous year in Gwangju, South Korea.
One of the main goals of this study was to charac-
terize the VP7 (G genotype) and VP4 (P genotype) genes
from RVs circulating in public. The predominant G
genotype was G1 (51.3%), followed by G2 (34.7%) and
G9 (10.8%). G2 and G4 RVs were the most frequently
detected genotypes out of the four common strains
(G1eG4) between 1998 and 2004 [20]. G1 was the most
predominant strain for a 10-year period prior to 1997
and during 2005e2009 in South Korea [14]. Recently,
human G9 strains became the fifth most common strain
found in the public sphere [21]. The first G9 strain,
WI91, was detected in children in the United States in
1983 [22] and was first detected in 2002 in South Korea
[14]. G9 has become recognized as one of the emerging
genotypes in many countries such as Cuba [23], France
[24], Mexico [25], the United States [26], and Libya
[27]. In this study, G9s were the third most identified
genotype and had a slightly greater predominance over
G3 and G4. These results suggest that the genotype G9
should be considered one of the serotypes of choice for
RV vaccines in the future. P[8] (66.1%) was the most
common genotype P, followed by P[4] (31.4%), P[6],
and P[9] (0.1%). This result is in agreement with pre-
vious data stating that P[8] was the most prevalent strain
in Korea and other countries [12,28]. Genotypes P[6]
and P[9] were detected less frequently; however, these
uncommon types continue to be of interest because of a
possible agent in RV vaccine programs.
Regarding GeP combinations, the G1P[8] (51.8%)
genotype combination was the most prevalent RV type
followed by G2P[4] (30.5%) in 2013. Previous studiesgju in 2013.





Figure 2. Distribution of major genotypes of rotavirus in Gwangju, with respect to vaccination or nonvaccination groups.
368 M.J. Kim, et alon RV circulation in South Korea from 2005 until 2007
have shown that G1P[8] (36%) was the predominant
type, followed by G2P[8] (16%), G4P[6] (8.9%), and
G1P[6] (8.2%) [14]. The prevalence of G2P[4] was
34.6% in 2000e2001 [29]. Recently, an increase in the
incidence of infection with the G2P[4] strain has been
reported in Brazil, where the monovalent G1P[8] vac-
cine is currently in use [30]. Also, reassortants of
common human strains, G9P[4] and G1P[4], and a
zoonotic genotype G4P[6] were also identified in south
Korea [29].
These studies suggest that the distribution of circu-
lating RV genotypes and predominant strains changes
from year to year and has been reported to differ in
different regions. Moreover, there are reassortments
between human RVs (P[8] and P[9]) or between human
and animal strains. Therefore, continuing surveillance is
important to monitor the changes in virus genotype
patterns and the appearance of new genotypes in each
country.
There were slight differences in the genotype distri-
bution in the patient groups with or without prior
vaccination. We conclude that the prevalence of specific
RV genotypes in a region changes each year, and non-
vaccine strains such as G9, P[4], P[6], and P[9] have
increased in Gwangju, South Korea. These emerging
strains should be considered as candidates for new RV
vaccines in the future.Conflicts of interest
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